2026-04-27T01:50:02Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/274332026-04-21T00:17:29Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Garcia-Pavia, Pablo author Kristen, Arnt V author Drachman, Brian author Carlsson, Martin author Amass, Leslie author Maurer, Mathew S author 2025-06 This summary describes results from a called the ( for short). In this study from THAOS, researchers looked at people with a heart condition called ( for short). Some people from this study took an approved treatment for ATTR-CM called and some did not. Researchers looked at how many people with ATTR-CM were alive after two and a half years and three and a half years. They also looked at the people had when they took tafamidis.In people who took tafamidis, an estimated 8 in 10 people (84%) were alive after two and a half years, and an estimated 8 in 10 people (77%) were alive after three and a half years. In people who did not take tafamidis, an estimated 7 in 10 people (70%) were alive after two and a half years, and an estimated 6 in 10 people (59%) were alive after three and a half years. The side effects people had while taking tafamidis in the THAOS study were similar to what has been reported in clinical studies.This real-world study supports the use of tafamidis for improving survival in people with ATTR-CM[Box: see text]. Future Cardiol. 2025 Jun;21(7):433-445. https://hdl.handle.net/20.500.12105/27433 40391408 Future Cardiology Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary.